Introduction
============

Intervertebral disc (IVD) degeneration, also termed degenerative disc disorder or degenerative disc disease, is a pathological process that may induce acute or chronic lower back pain ([@b1-mmr-16-01-0553],[@b2-mmr-16-01-0553]). Lower back pain is one of the primary health problems in developed countries ([@b3-mmr-16-01-0553]). The risk factors for disc degeneration include genetic inheritance and environmental risk factors, including smoking cigarettes and repetitive and high mechanical loading ([@b4-mmr-16-01-0553]). IVD degeneration is a rapidly progressing disease without an effective therapeutic method ([@b5-mmr-16-01-0553]). Therefore, it is necessary to explore the mechanisms of IVD degeneration in order to be able to develop a novel treatment scheme.

IVD degeneration and the underlying molecular mechanisms have been previously investigated. The aggrecanases ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS)-1, -4, -5, -9 and -15 may promote extracellular matrix (ECM) alterations during IVD degeneration, and may be used for preventing IVD degeneration and its morbidity ([@b6-mmr-16-01-0553]). In disc cells, reduced expression of SRY-type high mobility group box 9 (*SOX9*) may be associated with disc degeneration and disc ageing via inhibition of type II collagen expression ([@b7-mmr-16-01-0553]). The growth differentiation factor-5 (*GDF-5*) cDNA and the recombinant GDF-5 protein may promote the expression of ECM protein-coding genes in mouse IVD cells ([@b8-mmr-16-01-0553]). Previous studies have detected overexpressed tumor necrosis factor α (*TNF*-α) and interleukin (*IL*)-1 in aged and degenerative IVDs obtained from human and animal models ([@b9-mmr-16-01-0553],[@b10-mmr-16-01-0553]). *IL-1* has been identified to be involved in IVD degeneration via directly inhibiting matrix synthesis and promoting matrix degradation ([@b11-mmr-16-01-0553],[@b12-mmr-16-01-0553]). Cytokines of *IL-1* and *TNF*-α may be associated with the pathogenesis of IVD degeneration; however, *IL-1* may have a greater contribution to IVD degeneration and may be a more suitable therapeutic target for the disease ([@b13-mmr-16-01-0553]).

In 2013, Markova *et al* ([@b14-mmr-16-01-0553]) established a rat disc organ culture model that mimicked IVD degeneration via culturing rat IVDs in the presence of IL-1β, TNF-α and serum-limiting conditions. They obtained 1036 differentially expressed genes (DEGs) between experimental and control groups following gene expression analysis for microarray data. The present study used the data from Markova *et al* ([@b14-mmr-16-01-0553]) and the DEGs between degenerated and normal nucleus pulposus cells were identified, and their possible functions were predicted using enrichment analysis. Additionally, protein-protein interaction (PPI) networks were visualized and module analysis was conducted to screen for key genes in degenerated nucleus pulposus cells.

Materials and methods
=====================

### Microarray data

Microarray data obtained from GSE42611 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42611>), which was downloaded from the database of Gene Expression Omnibus (GEO), were sequenced on the platform of GPL6247 Affymetrix Rat Gene 1.0 ST Array \[transcript (gene) version\]. GSE42611 included 4 nucleus pulposus samples isolated from degenerated IVDs and 4 nucleus pulposus samples separated from normal IVDs. The procedure that had been used to obtain the rat lumbar disc specimens (n=4 specimens/group) was as follows, according to the method of Ponnappan *et al* ([@b8-mmr-16-01-0553]): Whole lumbar IVDs with endplates had been dissected and preserved in organ culture. Lumbar discs in the experimental group had been cultivated in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 100 ng/ml TNF-α, 10 ng/ml IL-1β, 50 µg/ml L-ascorbate, 40 mM NaCl, 1% fetal bovine serum (FBS), antibiotics and antimycotics. Lumbar discs in the control group had been cultured in DMEM containing 50 µg/ml L-ascorbate, 40 mM NaCl, 10% FBS and antibiotics without cytokines. The discs had been cultured for a total of 10 days ([@b14-mmr-16-01-0553]). GSE42611 used in this study was downloaded from a public database; therefore, patient consent or ethics committee approval were not required.

### Data preprocessing and DEGs screening

GSE42611 was downloaded and the microarray data was preprocessed using the Affy package ([@b15-mmr-16-01-0553]) in R. The process of data preprocessing included background correction, quantile normalization, summarization and probe ID to gene symbol transformation. Linear models for microarray data in the limma package ([@b16-mmr-16-01-0553]) in R were used to analyze the DEGs between degenerated and normal nucleus pulposus cells. P-values of the DEGs were calculated separately and adjusted using the t-test method and the Benjamini & Hochberg method ([@b17-mmr-16-01-0553]). P\<0.05 and \|log~2~ fold-change (FC)\|\>1 were used as the thresholds.

### Functional and pathway enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery (DAVID; [david.abcc.ncifcrf.gov](david.abcc.ncifcrf.gov)) software was used to interpret functions of extensive genes obtained from previous genome studies ([@b18-mmr-16-01-0553]). The Gene Ontology database (GO; [www.geneontology.org](www.geneontology.org)) contained structured ontologies or vocabularies that depict basic characteristics of genes and gene products ([@b19-mmr-16-01-0553]). The Kyoto Encyclopedia of Genes and Genomes database (KEGG; [www.genome.jp/kegg/](www.genome.jp/kegg/)) synthesizes information of biological systems from genomic, chemical and systemic functional aspects ([@b20-mmr-16-01-0553]). Using the DAVID software, functional and pathway enrichment analyses were conducted separately, for upregulated and downregulated genes. P≤0.05 and \>2 enriched genes were set as the thresholds.

### PPI network construction and module analysis

The Search Tool for the Retrieval of Interacting Genes (STRING; [string-db.org](string-db.org)) database provide comprehensive and easily accessible interaction information derived from experiments and predictions ([@b21-mmr-16-01-0553]). Cytoscape software ([www.cytoscape.org](www.cytoscape.org)) was used to integrate high-throughput expression data and biomolecular interaction networks into a unified framework ([@b22-mmr-16-01-0553]). The PPIs obtained for the DEGs were searched using the STRING database ([@b21-mmr-16-01-0553]), with the required confidence (combined score) \>0.4 as the threshold. Using Cytoscape software version 2.8 ([@b22-mmr-16-01-0553]), the PPIs were used to established a PPI network. In the network, the proteins were termed nodes and the number of edges involved were their degrees. Finally, the MCODE plug-in ([@b23-mmr-16-01-0553]) in Cytoscape was used to perform module analysis of the PPI networks. The parameters were set at the default thresholds.

Results
=======

### DEG analysis

P\<0.05 and \|log~2~FC\|\>1 were set as thresholds and the DEGs between degenerated and normal nucleus pulposus cells were analyzed. There were 558 DEGs identified in the degenerated nucleus pulposus cells compared with normal nucleus pulposus cells, including 253 upregulated and 305 downregulated genes. There were more downregulated genes compared with upregulated genes.

### Functional and pathway enrichment analysis

The upregulated genes in the degenerated nucleus pulposus cells were significantly enriched in 255 GO terms and 9 KEGG pathways. The top 10 functions are presented in [Table IA](#tI-mmr-16-01-0553){ref-type="table"}, including response to wounding (P=2.35×10^−8^), inflammatory response (P=5.99×10^−8^) and response to organic substance (P=1.56×10^−7^).

The downregulated genes in the degenerated nucleus pulposus cells were significantly enriched in 263 GO terms and 10 KEGG pathways. The top 10 functions included M phase (P=9.18×10^−12^), cell cycle phase (P=2.81×10^−10^) and response to steroid hormone stimulus (P=2.95×10^−9^; [Table IB](#tI-mmr-16-01-0553){ref-type="table"}).

Additionally, the upregulated genes were significantly enriched in cytokine-cytokine receptor interaction (P=2.86×10^−4^), apoptosis (P=3.95×10^−4^) and chemokine (P=1.60×10^−3^; [Table IIA](#tII-mmr-16-01-0553){ref-type="table"}) signaling pathways.

The pathways enriched for the downregulated genes included ECM-receptor interaction \[P=1.17×10^−11^, involving thrombospondin 1 (*THBS1*)\], focal adhesion (P=1.90×10^−9^) and hematopoietic cell lineage (P=3.12×10^−3^; [Table IIB](#tII-mmr-16-01-0553){ref-type="table"}).

### PPI network construction and module analysis

PPI networks were constructed by Cytoscape software following a PPI search of the DEGs. The PPI networks for the upregulated ([Fig. 1](#f1-mmr-16-01-0553){ref-type="fig"}) and the downregulated ([Fig. 2](#f2-mmr-16-01-0553){ref-type="fig"}) genes separately had 360 and 1,112 interactions. Notably, IL-6 (degree=39) in the PPI network for the upregulated genes and vascular endothelial growth factor A (VEGFA; degree=37) in the PPI network for the downregulated genes had higher degrees. Using the MCODE plug-in in Cytoscape, four modules (µM1, µM2, µM3 and µM4) were identified from the PPI network for the upregulated genes ([Fig. 3](#f3-mmr-16-01-0553){ref-type="fig"}). Meanwhile, four modules (dM1, dM2, dM3 and dM4) were identified from the PPI network for the downregulated genes ([Fig. 4](#f4-mmr-16-01-0553){ref-type="fig"}). It is of note that collagen, type I, α1 (COL1A1), COL1A2, COL3A1, COL5A2, COL6A1, COL6A2, COL6A3, COL11A1, COL12A1 and integrin α4 (ITGA4) may interact with each other in the dM2 module.

The top 5 functions enriched for the upregulated genes in modules included taxis (µM1; P=1.03×10^−8^), response to organic substance (µM2; P=1.21×10^−4^), response to cytokine stimulus (µM3; P=5.04×10^−4^) and chemical homeostasis (µM4, P=1.22×10^−3^; [Table IIIA](#tIII-mmr-16-01-0553){ref-type="table"}). The pathways enriched for the upregulated genes in modules included the chemokine signaling pathway (µM1; P=1.10×10^−4^) and the Jak-STAT signaling pathway (µM2; P=7.69 ×10^−4^; [Table IIIB](#tIII-mmr-16-01-0553){ref-type="table"}). Additionally, the top 5 functions enriched for the downregulated genes in modules, included M phase (dM1; P=2.70×10^−16^), extracellular matrix organization (dM2; P=1.79×10^−7^, including *COL3A1*, *COL1A2*, *COL1A1*, *COL11A1* and *COL5A2*), G-protein coupled receptor protein signaling pathway (dM3; P=7.27×10^−4^) and wound healing (dM4; P=1.56 ×10^−4;^ [Table IVA](#tIV-mmr-16-01-0553){ref-type="table"}). The pathways enriched for the downregulated genes in modules included cell cycle (dM1; P=4.40×10^−5^), ECM-receptor interaction (dM2; P=1.37×10^−15^, including *COL3A1*, *COL6A3*, *COL1A2*, *COL6A2*, *COL6A1*, *ITGA4*, *COL1A1*, *COL11A1* and *COL5A2*) and neuroactive ligand-receptor interaction (dM3; P=9.49×10^−4^; [Table IVB](#tIV-mmr-16-01-0553){ref-type="table"}).

Discussion
==========

The present study identified a total of 558 DEGs in degenerated nucleus pulposus cells compared with normal nucleus pulposus cells, including 253 upregulated and 305 downregulated genes. Using the MCODE plug-in in Cytoscape, four modules (µM1, µ0M2, µM3 and µM4) were identified from the PPI network for the upregulated genes. Additionally, four modules (dM1, dM2, dM3 and dM4) were identified from the PPI network for the downregulated genes.

A previous study demonstrated that genetic variations of *IL-6* may be associated with IVD degeneration, accompanied by sciatica ([@b24-mmr-16-01-0553]). *VEGFA* was overexpressed in the nucleus pulposus and affects the survival of nucleus pulposus cells in an autocrine/paracrine manner ([@b25-mmr-16-01-0553]). Injuries of IVDs may lead to increased VEGF levels, indicating that VEGF may be associated with discogenic back pain ([@b26-mmr-16-01-0553]). Under co-culture conditions, VEGF induction may contribute to neo-vascularization of IVD tissue and may function in the resorption of herniated discs ([@b27-mmr-16-01-0553]). The findings of the present study indicated that IL-6 (degree=39) in the PPI network for the upregulated genes and VEGFA (degree=37) in the PPI network for the downregulated genes had higher degrees. Therefore, *IL6* and *VEGFA* may be key genes involved in IVD degeneration. A previous study observed the immunolocalization of THBS in human IVD ([@b28-mmr-16-01-0553]). *THBS1* and *THBS2* are promising susceptibility genes in lumbar-disc herniation (LDH) that mediate the expression levels of matrix metalloproteinases (MMPs) 2 and 9, which are critical effectors of ECM remodeling ([@b29-mmr-16-01-0553]). Mice with *THBS1* or *THBS2* deficiency exhibit abnormal spine curvature ([@b30-mmr-16-01-0553]). Pathway enrichment performed in the present study revealed that downregulated *THBS1* was enriched in ECM-receptor interactions, suggesting that *THBS1* may have an important role in IVD degeneration.

The sequence variation of the regulatory region of *COL1A1* is closely associated with lumbar disc disease (LDD) in young military recruits who are newly diagnosed ([@b31-mmr-16-01-0553]). Ribosomal protein L8, ribosomal protein S16 and ribosomal protein S23 have been identified to contribute to protein synthesis, and *COL3A1* was involved in skeletal system processes in disc degeneration (DD), indicating that they may be used for diagnosis and therapy of DD ([@b32-mmr-16-01-0553]). Polymorphisms of the *COL9* and *COL11* genes contribute to the progression of degenerative lumbar spinal stenosis ([@b33-mmr-16-01-0553]). *COL11A1* expression level was reduced in the IVD of patients with LDH and it had a negative association with the severity of disc degeneration in patients with LDH ([@b34-mmr-16-01-0553]). In the dM2 module identified by the present study, COL1A1, COL1A2, COL3A1, COL5A2, COL6A1, COL6A2, COL6A3, COL11A1, COL12A1 and ITGA4 may interact with each other. Functional enrichment indicated that collagen genes were enriched in ECM organization. Therefore, collagen genes may contribute to the progression of IVD degeneration. Additionally, *ITGA4* may also be implicated in IVD degeneration via interaction with collagen genes.

In conclusion, the present study investigated the underlying mechanisms of IVD degeneration via bioinformatics analysis. A total 558 DEGs were screened in the degenerated nucleus pulposus cells. *IL6*, *VEGFA*, *THBS1*, *ITGA4* and collagen genes may be involved in the progression of IVD degeneration. These results suggested that the manipulation of these genes and their products may have potential as a novel therapeutic strategy for the treatment of patients with IVD. However, these findings were obtained by bioinformatics prediction and require further confirmation via further experimental studies.
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###### 

The top 10 enriched functions for the differentially expressed genes in the degenerated nucleus pulposus cells

  A, Top 10 functions enriched for the upregulated genes in the degenerated nucleus pulposus cells                                                                                     
  ---------------------------------------------------------------------------------------------------- ---------------------------------------------- -------------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0009611                                                                                           Response to wounding                           2.35×10^−8^    24                *KNG1, CXCL1, NFKBIZ, IL6, GIP, KNG2, OLR1, C3, CXCL3, KNG1L1, CXCL2, CLU, HP, GLI3, TIMP1, SOD2, ORM1, CASP4, HIF1A, CCL20, PTGES, HMOX1, JAK2, TFPI2*
  GO:0006954                                                                                           Inflammatory response                          5.99×10^−8^    17                *KNG1, CXCL1, NFKBIZ, IL6, KNG2, OLR1, C3, CXCL3, CXCL2, KNG1L1, HP, ORM1, CASP4, HIF1A, CCL20, PTGES, HMOX1*
  GO:0010033                                                                                           Response to organic substance                  1.56×10^−7^    35                *FOSL2, OSMR, IL6ST, TLR2, NFKBIA, HP, GNG12, MMP3, GLI3, TIMP1, GCH1, IRAK3, PTGES, HMOX1, CSF2RB, ANGPT1, PPP3CA, SKIL, PIK3R3, NR1H3, IL6, SGK1, GIP, BCKDHB, MMP14, CYP7B1, HIF1A, ATP2A2, ABCB1B, CXCL16, JAK2, CTSC, PTPN1, CAR4, STEAP2*
  GO:0006952                                                                                           Defense response                               1.68×10^−7^    22                *KNG1, CXCL1, NFKBIZ, IL6, KNG2, OLR1, FGR, C3, CXCL3, KNG1L1, CXCL2, TLR2, HP, GCH1, ORM1, CASP4, HIF1A, CCL20, PTGES, CXCL16, HMOX1, NOS2*
  GO:0042311                                                                                           Vasodilation                                   2.48×10^−6^      7               *KNG1, EDNRB, KNG2, KNG1L1, ITGA1, SOD2, GCH1*
  GO:0034097                                                                                           Response to cytokine stimulus                  3.62×10^−6^    11                *IRAK3, IL6, FOSL2, OSMR, IL6ST, PTGES, CXCL16, SKIL, MMP3, TIMP1, GCH1*
  GO:0009719                                                                                           Response to endogenous stimulus                4.73×10^−6^    24                *SGK1, IL6, FOSL2, GIP, BCKDHB, TLR2, HP, GNG12, MMP14, MMP3, GLI3, TIMP1, HIF1A, ATP2A2, ABCB1B, HMOX1, ANGPT1, JAK2, PTPN1, PPP3CA, PIK3R3, STEAP2, CAR4, NR1H3*
  GO:0009725                                                                                           Response to hormone stimulus                   8.64×10^−6^    22                *SGK1, IL6, FOSL2, GIP, BCKDHB, TLR2, HP, GNG12, MMP14, GLI3, TIMP1, HIF1A, ATP2A2, ABCB1B, HMOX1, ANGPT1, JAK2, PTPN1, STEAP2, CAR4, PIK3R3, NR1H3*
  GO:0055066                                                                                           Di-, tri-valent inorganic cation homeostasis   1.15×10^−5^    14                *KNG1, IL6ST, HEXB, SOD2, SLC11A2, EDNRB, HIF1A, MT1A, ATP2A2, HMOX1, MT2A, PKD2, JAK2, CP*
  GO:0055080                                                                                           Cation homeostasis                             1.82×10^−5^    15                *KNG1, SGK1, IL6ST, HEXB, SOD2, SLC11A2, EDNRB, HIF1A, MT1A, ATP2A2, HMOX1, MT2A, PKD2, JAK2, CP*
                                                                                                                                                                                       
  B, Top 10 enriched functions for the downregulated genes in the degenerated nucleus pulposus cells                                                                                   
                                                                                                                                                                                       
  ID                                                                                                   Description                                    P-value        Number of genes   Gene
                                                                                                                                                                                       
  GO:0000279                                                                                           M phase                                        9.18×10^−12^   21                *KIF11, MKI67, SGOL2, DLGAP5, HAUS1, NUF2, NUSAP1, CENPF, BIRC5, NDC80, CEP55, TACC3, CCNB1, KIF2C, PLK1, TUBB5, BUB1B, MNS1, SKA3, STMN1, CDCA3*
  GO:0048545                                                                                           Response to steroid hormone stimulus           2.95×10^−9^    23                *SOCS2, AIF1, CRYAB, IL1RN, TGFB3, IGF1, BIRC5, AQP1, MMP2, ADIPOQ, TIMP3, H19, CCND1, KRT19, CD36,SERPINF1, ADM, AVPR1A, FABP4, RARA, COL1A1, CD24, CCNA2*
  GO:0009628                                                                                           Response to abiotic stimulus                   1.09×10^−8^    26                *RBP4, APOBEC1, GCLC, AIF1, LXN, IL18, COL3A1, MMP2, CXCL12, TIMP3, KRT8, THBS1, COL11A1, MYOF, PTPRC, CRYAB, ATP1A3, IGF1, SNAI2, CCND1, CD36, ADM, FYN, AVPR1A, TGFB1I1, COL1A1*
  GO:0022610                                                                                           Biological adhesion                            1.23×10^−8^    28                *IBSP, COL3A1, LMO7, KITLG, ITGBL1, FAT3, CD93, COMP, ACAN, COL12A1, TNN, CD4, EMB, CD24, THBS1, COL11A1, THBS4, PTPRC, ACTN1, ITGA4, PCDH18, THY1, OMD, COL14A1, CD36, PECAM1, DSC2, CDH11*
  GO:0007155                                                                                           Cell adhesion                                  1.23×10^−8^    28                *IBSP, COL3A1, LMO7, KITLG, ITGBL1, FAT3, CD93, COMP, ACAN, COL12A1, TNN, CD4, EMB, CD24, THBS1, COL11A1, THBS4, PTPRC, ACTN1, ITGA4, PCDH18, THY1, OMD, COL14A1, CD36, PECAM1, DSC2, CDH11*
  GO:0051301                                                                                           Cell division                                  2.09×10^−8^    16                *RBP4, HAUS1, NUF2, NUSAP1, BIRC5, CEP55, CCNB1, CCND1, CCNB2, PLK1, BUB1B, SKA3, TOP2A, CCNA2, ASPM, CDCA3*
  GO:0022402                                                                                           Cell cycle process                             2.49×10^−8^    24                *GAS2L3, KIF11, MKI67, SGOL2, DLGAP5, HAUS1, NUF2, NUSAP1, CENPF, BIRC5, NDC80, CEP55, TACC3, CDKN3, CCNB1, KIF2C, CCND1, PLK1, TUBB5, BUB1B, MNS1, SKA3, STMN1, CDCA3*
  GO:0030199                                                                                           Collagen fibril organization                   4.36×10^−8^      8               *COL3A1, COL1A2, ACAN, COL1A1, COL11A1, COL5A2, SERPINH1, DPT*
  GO:0007049                                                                                           Cell cycle                                     4.42×10^−8^    27                *GAS2L3, S100A6, HAUS1, CEP55, KIF2C, TUBB5, MNS1, SKA3, CCNA2, CDCA3, KIF11, MKI67, SGOL2, DLGAP5, NUF2, CENPF, NUSAP1, BIRC5, NDC80, TACC3, CDKN3, CCNB1, CCND1, CCNB2, PLK1, BUB1B, STMN1*

###### 

Enriched pathways for the differentially expressed genes in the degenerated nucleus pulposus cells.

  A, Pathways enriched for the upregulated genes                                                                   
  -------------------------------------------------- ---------------------------------------- -------------- ----- -----------------------------------------------------------------------------------------------------------------------------------------------
  rno04060                                           Cytokine-cytokine receptor interaction   2.86×10^−4^    12    *TNFRSF9, IL6, ZCCHC2, IL23R, TNFSF11, OSMR, IL6ST, CXCL16, MET, CXCL2, CSF2RB, IL13RA1*
  rno04210                                           Apoptosis                                3.95×10^−4^      8   *CFLAR, IRAK3, CSF2RB, NFKBIA, NFKB1, PPP3CA, BIRC3, PIK3R3*
  rno04062                                           Chemokine signaling pathway              1.60×10^−3^    10    *CXCL1, FGR, CCL20, CXCL16, CXCL2, NFKBIA, JAK2, NFKB1, GNG12, PIK3R3*
  rno04621                                           NOD-like receptor signaling pathway      3.04×10^−3^      6   *CXCL1, IL6, CXCL2, NFKBIA, NFKB1, BIRC3*
  rno04630                                           Jak-STAT signaling pathway               6.77×10^−3^      8   *IL6, IL23R, OSMR, IL6ST, CSF2RB, JAK2, PIK3R3, IL13RA1*
  rno04620                                           Toll-like receptor signaling pathway     1.45×10^−2^      6   *IL6, MAP3K8, TLR2, NFKBIA, NFKB1, PIK3R3*
  rno05200                                           Pathways in cancer                       3.02×10^−2^    11    *IL6, HIF1A, EPAS1, MET, NFKBIA, NFKB1, NOS2, RUNX1, BIRC3, PIK3R3, GLI3*
  rno00230                                           Purine metabolism                        3.71×10^−2^      7   *XDH, GDA, PDE7A, PDE4B, PDE10A, AMPD3, NT5E*
  rno05222                                           Small cell lung cancer                   4.41×10^−2^      5   *NFKBIA, NFKB1, NOS2, BIRC3, PIK3R3*
                                                                                                                   
  B, Pathways enriched for the downregulated genes                                                                 
                                                                                                                   
  rno04512                                           ECM-receptor interaction                 1.17×10^−11^   16    *IBSP, COL3A1, ITGA4, COL5A2, HMMR, CD36, COMP, COL6A3, COL1A2, COL6A2, COL6A1, TNN, COL1A1, THBS1, COL11A1, THBS4*
  rno04510                                           Focal adhesion                           1.90×10^−9^    20    *IBSP, COL3A1, IGF1, ACTN1, ITGA4, COL5A2, CCND1, FYN, COMP, VEGFA, COL6A3, COL1A2, COL6A2, COL6A1, TNN, COL1A1, THBS1, COL11A1, FIGF, THBS4*
  rno04640                                           Hematopoietic cell lineage               3.12×10^−3^      7   *CD36, KITLG, CD4, ANPEP, CD24, ITGA4, CSF1R*
  rno05200                                           Pathways in cancer                       5.58×10^−3^    14    *FGF7, TGFB3, EGLN3, KITLG, IGF1, BIRC5, FZD4, MMP2, CCND1, VEGFA, RARA, FGF1, FIGF, CSF1R*
  rno04670                                           Leukocyte transendothelial migration     1.97×10^−2^      7   *CYBB, PECAM1, ACTN1, ITGA4, MMP2, CXCL12, THY1*
  rno05219                                           Bladder cancer                           2.86×10^−2^      4   *CCND1, VEGFA, MMP2, FIGF*
  rno04110                                           Cell cycle                               2.93×10^−2^      7   *CCNB1, CCND1, CCNB2, PLK1, TGFB3, BUB1B, CCNA2*
  rno04115                                           p53 signaling pathway                    3.38×10^−2^      5   *CCNB1, CCND1, CCNB2, SERPINE1, IGF1*
  rno04610                                           Complement and coagulation cascades      4.07×10^−2^      5   *C1QA, C3AR1, C5AR1, MASP1, SERPINE1*
  rno03320                                           PPAR signaling pathway                   4.25×10^−2^      5   *LPL, CD36, FABP4, ADIPOQ, PLTP*

###### 

Top 5 functions and pathways enriched for the upregulated genes in µM1, µM2, µM3 and µM4 modules.

  A, Top 5 functions enriched for the upregulated genes in µM1, µM2, µM3 and µM4 modules                                                                                                                                              
  ---------------------------------------------------------------------------------------- ------------ --------------------------------------------------------------------------------------------- ------------- ----------------- --------------------------------------------
  µM1                                                                                      GO:0042330   Taxis                                                                                         1.03×10^−8^   5                 *CXCL1, CCL20, CXCL16, CXCL3, CXCL2*
                                                                                           GO:0006935   Chemotaxis                                                                                    1.03×10^−8^   5                 *CXCL1, CCL20, CXCL16, CXCL3, CXCL2*
                                                                                           GO:0006952   Defense response                                                                              3.82×10^−8^   6                 *KNG1, CXCL1, CCL20, CXCL16, CXCL3, CXCL2*
                                                                                           GO:0007626   Locomotory behavior                                                                           4.20×10^−7^   5                 *CXCL1, CCL20, CXCL16, CXCL3, CXCL2*
                                                                                           GO:0006954   Inflammatory response                                                                         4.97×10^−7^   5                 *KNG1, CXCL1, CCL20, CXCL3, CXCL2*
  µM2                                                                                      GO:0010033   Response to organic substance                                                                 1.21×10^−4^   6                 *IL6, OSMR, IL6ST, HMOX1, PTPN1, PIK3R3*
                                                                                           GO:0042127   Regulation of cell proliferation                                                              5.31×10^−4^   5                 *IL6, OSMR, IL6ST, HMOX1, SOD2*
                                                                                           GO:0010035   Response to inorganic substance                                                               5.55×10^−4^   4                 *IL6, HMOX1, NFKB1, SOD2*
                                                                                           GO:0007167   Enzyme-linked receptor protein signaling pathway                                              6.31×10^−4^   4                 *IL6ST, MET, PTPN1, PIK3R3*
                                                                                           GO:0031667   Response to nutrient levels                                                                   6.44×10^−4^   4                 *IL6, IL6ST, HMOX1, SOD2*
  µM3                                                                                      GO:0034097   Response to cytokine stimulus                                                                 5.04×10^−4^   3                 *FOSL2, MMP3, TIMP1*
                                                                                           GO:0009719   Response to endogenous stimulus                                                               1.26×10^−2^   3                 *FOSL2, MMP3, TIMP1*
                                                                                           GO:0006508   Proteolysis                                                                                   2.26×10^−2^   3                 *ADAMTS1, MMP3, ADAMTS4*
                                                                                           GO:0010033   Response to organic substance                                                                 3.18×10^−2^   3                 *FOSL2, MMP3, TIMP1*
                                                                                           GO:0007568   Aging                                                                                         4.87×10^−2^   2                 *FOSL2, TIMP1*
  µM4                                                                                      GO:0048878   Chemical homeostasis                                                                          1.22×10^−3^   4                 *SLC11A2, SGK1, HIF1A, EPAS1*
                                                                                           GO:0043619   Regulation of transcription from RNA polymerase II promoter in response to oxidative stress   2.48×10^−3^   2                 *HIF1A, EPAS1*
                                                                                           GO:0043618   Regulation of transcription from RNA polymerase II promoter in response to stress             2.97×10^−3^   2                 *HIF1A, EPAS1*
                                                                                           GO:0043620   Regulation of transcription in response to stress                                             2.97×10^−3^   2                 *HIF1A, EPAS1*
                                                                                           GO:0042592   Homeostatic process                                                                           3.58×10^−3^   4                 *SLC11A2, SGK1, HIF1A, EPAS1*
                                                                                                                                                                                                                                      
  B, Pathways enriched for the upregulated genes in µM1 and µM2 modules                                                                                                                                                               
                                                                                                                                                                                                                                      
  Module                                                                                   ID           Description                                                                                   P-value       Number of genes   Gene
                                                                                                                                                                                                                                      
  µM1                                                                                      rno04062     Chemokine signaling pathway                                                                   1.10×10^−4^   4                 *CXCL1, CCL20, CXCL16, CXCL2*
                                                                                           rno04621     NOD-like receptor signaling pathway                                                           4.36×10^−2^   2                 *CXCL1, CXCL2*
  µM2                                                                                      rno04630     Jak-STAT signaling pathway                                                                    7.69×10^−4^   4                 *IL6, OSMR, IL6ST, PIK3R3*
  µM2                                                                                      rno04060     Cytokine-cytokine receptor interaction                                                        2.12×10^−3^   4                 *IL6, OSMR, IL6ST, MET*
                                                                                           rno04620     Toll-like receptor signaling pathway                                                          6.74×10^−3^   3                 *IL6, NFKB1, PIK3R3*
                                                                                           rno05200     Pathways in cancer                                                                            8.17×10^−3^   4                 *IL6, MET, NFKB1, PIK3R3*

###### 

Top 5 functions and pathways enriched for the downregulated genes in dM1, dM2, dM3 and dM4 modules.

  A, Top 5 functions enriched for the downregulated genes                                                                                                        
  --------------------------------------------------------- ------------ ------------------------------------------------------ -------------- ----------------- ----------------------------------------------------------------------------------------------------
  dM1                                                       GO:0000279   M phase                                                2.70×10^−16^   12                *CCNB1, KIF2C, KIF11, MKI67, PLK1, DLGAP5, NUF2, NUSAP1, BUB1B, CENPF, BIRC5, CEP55*
                                                            GO:0007049   Cell cycle                                             6.52×10^−15^   14                *KIF11, MKI67, DLGAP5, NUF2, NUSAP1, CENPF, BIRC5, CEP55, CDKN3, CCNB1, KIF2C, PLK1, BUB1B, CCNA2*
                                                            GO:0022403   Cell cycle phase                                       7.11×10^−15^   12                *CCNB1, KIF2C, KIF11, MKI67, PLK1, DLGAP5, NUF2, NUSAP1, BUB1B, CENPF, BIRC5, CEP55*
                                                            GO:0022402   Cell cycle process                                     1.48×10^−14^   13                *KIF11, MKI67, DLGAP5, NUF2, NUSAP1, CENPF, BIRC5, CEP55, CDKN3, CCNB1, KIF2C, PLK1, BUB1B*
                                                            GO:0000087   M phase of mitotic cell cycle                          1.70×10^−14^   10                *CCNB1, KIF11, PLK1, DLGAP5, NUF2, NUSAP1, BUB1B, CENPF, BIRC5, CEP55*
  dM2                                                       GO:0030199   Collagen fibril organization                           5.72×10^−10^     5               *COL3A1, COL1A2, COL1A1, COL11A1, COL5A2*
                                                            GO:0030198   Extracellular matrix organization                      1.79×10^−7^      5               *COL3A1, COL1A2, COL1A1, COL11A1, COL5A2*
                                                            GO:0043588   Skin development                                       6.89×10^−7^      4               *COL3A1, COL1A2, COL1A1, COL5A2*
                                                            GO:0043062   Extracellular structure organization                   1.10×10^−6^      5               *COL3A1, COL1A2, COL1A1, COL11A1, COL5A2*
                                                            GO:0001501   Skeletal system development                            1.45×10^−5^      5               *COL3A1, COL1A2, COL1A1, COL11A1, COL5A2*
  dM3                                                       GO:0007186   G-protein coupled receptor protein signaling pathway   7.27×10^−4^      6               *S1PR3, C3AR1, C5AR1, PENK, LPAR1, CXCL12*
                                                            GO:0007610   Behavior                                               7.91×10^−4^      4               *C3AR1, C5AR1, PENK, CXCL12*
                                                            GO:0002430   Complement receptor mediated signaling pathway         9.92×10^−4^      2               *C3AR1, C5AR1*
                                                            GO:0007204   Elevation of cytosolic calciumion concentration        1.03×10^−3^      3               *C3AR1, C5AR1, LPAR1*
                                                            GO:0051480   Cytosolic calcium ion homeostasis                      1.29×10^−3^      3               *C3AR1, C5AR1, LPAR1*
  dM4                                                       GO:0042060   Wound healing                                          1.56×10^−4^      4               *SERPINE1, TGFB3, IGF1, GAS6*
                                                            GO:0040007   Growth                                                 2.91×10^−4^      4               *SERPINE1, TGFB3, IGF1, GAS6*
                                                            GO:0042246   Tissue regeneration                                    3.74×10^−4^      3               *SERPINE1, IGF1, GAS6*
                                                            GO:0007167   enzyme linked receptor protein signaling pathway       6.31×10^−4^      4               *TGFB3, IGF1, FIGF, CSF1R*
                                                            GO:0051094   Positive regulation of developmental process           8.57×10^−4^      4               *TGFB3, IGF1, FIGF, CSF1R*
  dM1                                                       rno04110     Cell cycle                                             4.40×10-5        4               CCNB1, PLK1, BUB1B, CCNA2
                                                            rno04914     Progesterone-mediated oocyte maturation                1.41×10-3        3               CCNB1, PLK1, CCNA2
                                                                                                                                                                 
  B, Pathways enriched for the downregulated genes                                                                                                               
                                                                                                                                                                 
  Module                                                    ID           Description                                            P-value        Number of genes   Gene
                                                                                                                                                                 
  dM2                                                       rno04512     ECM-receptor interaction                               1.37×10^−15^   9                 *COL3A1, COL6A3, COL1A2, COL6A2, COL6A1, ITGA4, COL1A1, COL11A1, COL5A2*
                                                            rno04510     Focal adhesion                                         1.91×10^−12^   9                 *COL3A1, COL6A3, COL1A2, COL6A2, COL6A1, ITGA4, COL1A1, COL11A1, COL5A2*
  dM3                                                       rno04080     Neuroactive ligand-receptor interaction                9.49×10^−4^    4                 *S1PR3, C3AR1, C5AR1, LPAR1*
  dM4                                                       rno05200     Pathways in cancer                                     5.33×10^−3^    4                 *TGFB3, IGF1, FIGF, CSF1R*
                                                            rno04510     Focal adhesion                                         2.26×10^−2^    3                 *IGF1, ACTN1, FIGF*

[^1]: Contributed equally
